Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Levetiracetam · 2 trials · 1 indication
| Arm | Type | Description |
|---|---|---|
| Levetiracetam | EXPERIMENTAL | Levetiracetam Tablets, 750 mg of Dr. Reddy's Laboratories Limited |
| Keppra® | ACTIVE_COMPARATOR | Keppra® 750 mg Tablets of UCB Pharma Inc., |
| Name | Type | Description |
|---|---|---|
| Levetiracetam | DRUG | Levetiracetam Tablets, 750 mg of Dr. Reddy's Laboratories Limited |
Inclusion Criteria: * Healthy adult male volunteers, 18 to 55 years of age; * Weighing at least 60 kg and within 15% of their ideal weights (Table of "Desirable Wights of Adults", Metropolitan Life Insurance Company, 1983); * Medically healthy subjects with clinically normal laboratory profiles and...
Levetiracetam is a small molecule drug developed by Dr. Reddy's Laboratories Ltd, which trades under the ticker RDY. It is being studied in Phase 1 clinical trials. The specific medical conditions it is intended to treat have not been disclosed. It belongs to the therapeutic area classified as Other.
Levetiracetam targets CACNA1B and SV2A. It acts as a blocker of these targets. CACNA1B is a calcium channel, and SV2A is a synaptic vesicle protein. This mechanism is under investigation in early-stage clinical trials.
Levetiracetam is being developed by Dr. Reddy's Laboratories Ltd, a pharmaceutical company that trades under the ticker symbol RDY. The company is responsible for the clinical development of this small molecule drug.
Levetiracetam is in Phase 1 clinical development. It is investigational and has not been approved by the FDA for any indication. The two completed Phase 1 trials were bioequivalence and bioavailability studies conducted in healthy male volunteers.
Levetiracetam has been studied in two completed Phase 1 trials: NCT01132352, a bioequivalence study under fed conditions, and NCT01131897, a bioavailability study under fasting conditions. Both enrolled 24 healthy male volunteers in the United States and are now completed.